## ACHC: Acadia Healthcare Company, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -13.6% below STRENGTH zone (4.0-10.0%); PEG 1.32 fails VALUE criteria (<1.0); RSI 29 oversold (REVERSION excluded per A/B test). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($11.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Acadia Healthcare (NASDAQ:ACHC) Stock Price Down 7.3% - Here's What Happened**
- Source: MarketBeat | 20251208T190932 | Neutral | Relevance: 99%
-  Acadia Healthcare's stock price dropped 7.3% on Monday on unusually light trading volume, closing at $14.3460. This decline follows several analyst downgrades, including Leerink Partnrs to "hold" and Mizuho cutting its price target. Although the company slightly beat Q3 EPS estimates, it missed revenue expectations and provided FY2025 guidance of 2.350â€“2.450 EPS.

**2. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Acadia Healthcare Company, Inc. (ACHC) and Encourages Stockholders to Learn More About the Investigation**
- Source: MyChamplainValley.com | 20251209T160911 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Acadia Healthcare Company, Inc. The firm encourages investors who purchased Acadia Healthcare securities before February 28, 2020, and still hold them, to come forward and assist in the investigation. Investors can find more information and contact the firm through their website or by phone.

**3. Bronstein, Gewirtz & Grossman, LLC Is Investigating Acadia Healthcare Company, Inc. (ACHC) And Encourages Stockholders to Connect**
- Source: WRIC ABC 8News | 20251210T001105 | Neutral | Relevance: 97%
-  Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Acadia Healthcare Company, Inc. (ACHC) after the company significantly lowered its full-year 2025 Adjusted EBITDA guidance due to much higher-than-expected patient-related litigation costs. The firm encourages stockholders who purchased Acadia securities to connect and assist with the investigation. This investigation follows a disclosure by Acadia Healthcare of increased PGLG expenses, primarily from patient-related litigation, impacting their financial outlook.

**4. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Acadia Healthcare Company, Inc. (ACHC) and Encourages Investors to Learn More About the Investigation**
- Source: Louisiana First News | 20251210T161105 | Neutral | Relevance: 97%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Acadia Healthcare Company, Inc. (ACHC) following the company's disclosure of higher anticipated expenses related to patient-related litigation. Acadia revised its full-year 2025 Adjusted EBITDA guidance downwards and projected a significant increase in PLGL expense due to higher settlement costs, increased claim frequency, and less favorable reinsurance terms. Investors who purchased Acadia securities are encouraged to learn more about the investigation.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 10)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Barclays | $14 | $17 | -18% |
| 2025-12-03 | RBC Capital | $19 | $22 | -14% |
| 2025-12-03 | Cantor Fitzgera | $17 | $22 | -23% |
| 2025-12-03 | Keybanc | $25 | $30 | -17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Barclays | main | Equal-Weight |
| 2025-12-03 | RBC Capital | main | Outperform |
| 2025-12-03 | Cantor Fitzgera | main | Neutral |
| 2025-12-03 | Keybanc | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 0 |

**Top Holders:**
- Blackrock Inc.: 11.9% (+20.4%)
- Vanguard Group Inc: 10.2% (+7.8%)
- Wellington Managemen: 10.2% (+11.8%)
- FMR, LLC: 6.6% (+2.2%)
- Khrom Capital Manage: 5.5% (+103.0%)

### Key Risks

1. High short interest (15.0%, 5.0 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 40.7% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.32 suggests fair value with growth premium. Analyst sentiment negative (10 target cuts vs 0 raises). Institutional flow bullish (9 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 0.90 |
| 52W Range | $12.63 - $47.08 |
| Short Interest | 15.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.32 |
| Forward P/E | 7.0 |
| Current P/E | 6.6 |
| YoY Growth | -5.3% |
| EPS Direction | FALLING |

### Technicals

MRS_20 weakening modestly (-0.7% over 5 days). Below STRENGTH zone by 17.6pp (needs >4.0% for momentum thesis). AM_20 at -11.4% indicates price below own 20MA trend. Underperforming sector by 10.1pp, stock-specific weakness. Below SMA200 (0.59x), long-term trend not supportive. RSI oversold at 29, potential bounce setup.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -13.56% (CS: 0) | Weak |
| RSI_14 | 29.2 | Oversold |
| MACD Histogram | 0.02 | Bullish |
| vs SMA20 | 0.886x | Below |
| vs SMA50 | 0.681x | Below |
| vs SMA200 | 0.593x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $13.75
- **Stop Loss:** $11.61 (15.6% risk)
- **Target:** $15.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 233
- **Position Value:** $3,203.75
- **Portfolio %:** 3.20%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-26 (Est: $0.13)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.66 | $0.72 | +9.2% |
| 2025Q2 | $0.71 | $0.83 | +17.4% |
| 2025Q1 | $0.36 | $0.40 | +12.0% |
| 2024Q4 | $0.71 | $0.64 | -10.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*